Payment overview · 2025
General Payments
$222,385.59
212 reported records · 21 companies
Healthcare provider profile · identity verified
David A Mclain, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · BIRMINGHAM, AL · NPI 1689614737
Verified facts
What the public records show
CMS Open Payments records show David A Mclain, M.D. received $222,385.59 in general payments during 2025 across 212 reported records.
ABBVIE INC. accounted for 98.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Benlysta, Enbrel, Orencia, Otezla, Prolia, Rinvoq, Saphnelo, Tremfya.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HUMIRA as an associated drug or biological on 1828 records involving 689 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Humira by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 168 claims for Rinvoq by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Enbrel by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Otezla by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SAPHNELO as an associated drug or biological on 16430 records involving 3390 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Saphnelo by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Eliquis by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ORENCIA as an associated drug or biological on 10404 records involving 2463 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Orencia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BENLYSTA as an associated drug or biological on 19884 records involving 5034 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Benlysta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TREMFYA as an associated drug or biological on 292917 records involving 40097 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Tremfya by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $217,890.42 | 98.0% | 47 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $956.99 | 0.4% | 44 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $666.29 | 0.3% | 20 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $487.79 | 0.2% | 13 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $392.49 | 0.2% | 13 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $311.83 | 0.1% | 18 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $276.26 | 0.1% | 15 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $275.68 | 0.1% | 9 | 2025 |
| Aurinia Pharma U.S., Inc. | Unresolved — no canonical attribution shown | $258.85 | 0.1% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $239.28 | 0.1% | 7 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $162.96 | 0.1% | 5 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $136.64 | 0.1% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $94.02 | 0.0% | 4 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $52.29 | 0.0% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.82 | 0.0% | 2 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $34.65 | 0.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.43 | 0.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.96 | 0.0% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $20.03 | 0.0% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.99 | 0.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.92 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Grant | $217,127.50 | 4 |
| Food and Beverage | $5,108.10 | 206 |
| Education | $149.99 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $217,655.27 | 34 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $585.21 | 17 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $487.79 | 13 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $311.83 | 18 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $275.68 | 9 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $267.22 | 5 | 2025 |
Source payment records
|
|||||
| LUPKYNIS Normalized: lupkynis |
Drug | Aurinia Pharma U.S., Inc. | $258.85 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $253.46 | 19 | 2025 |
Source payment records
|
|||||
| KEVZARA Normalized: kevzara |
Biological | GENZYME CORPORATION | $239.28 | 7 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $218.95 | 11 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $217.30 | 10 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $171.13 | 11 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $162.96 | 5 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $136.64 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $130.53 | 12 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $102.58 | 4 | 2025 |
Source payment records
|
|||||
| ORENCIA Normalized: orencia |
Biological | E.R. Squibb & Sons, L.L.C. | $94.02 | 4 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $79.33 | 3 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $68.27 | 5 | 2025 |
Source payment records
|
|||||
| CUTAQUIG Normalized: cutaquig |
Biological | PFIZER INC. | $52.88 | 2 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $52.29 | 3 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $35.06 | 3 | 2025 |
Source payment records
|
|||||
| TALTZ Normalized: taltz |
Drug | Lilly USA, LLC | $29.43 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.43 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $27.47 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $25.96 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $25.80 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $25.80 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.54 | 3 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.74 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.85 | 1 | 2025 |
Source payment records
|
|||||
| HADLIMA Normalized: hadlima |
Drug | Organon LLC | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $16.41 | 1 | 2025 |
Source payment records
|
|||||
| SOVUNA Normalized: sovuna |
Drug | ANI Pharmaceuticals, Inc. | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.92 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $7.45 | 1 | 2025 |
Source payment records
|
|||||
| ENBREL Normalized: enbrel |
Biological | Amgen Inc. | $3.44 | 1 | 2025 |
Source payment records
|
|||||
| VELSIPITY Normalized: velsipity |
Drug | PFIZER INC. | $2.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BENLYSTA benlysta |
2025 | Benlysta | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ENBREL enbrel |
2025 | Enbrel | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ORENCIA orencia |
2025 | Orencia | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 59 | exact normalized | Medicare Part D |
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 168 | exact normalized | Medicare Part D |
| SAPHNELO saphnelo |
2025 | Saphnelo | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TREMFYA tremfya |
2025 | Tremfya | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | HUMIRA open payments reported associated product |
CMS Open Payments — General Payments 1828 supporting records · 689 recipient NPIs · example record 1201353784 |
Humira · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
168 | 24 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
59 | 37 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SAPHNELO open payments reported associated product |
CMS Open Payments — General Payments 16430 supporting records · 3390 recipient NPIs · example record 1206131348 |
Saphnelo · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ORENCIA open payments reported associated product |
CMS Open Payments — General Payments 10404 supporting records · 2463 recipient NPIs · example record 1184378623 |
Orencia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | BENLYSTA open payments reported associated product |
CMS Open Payments — General Payments 19884 supporting records · 5034 recipient NPIs · example record 1190332353 |
Benlysta · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | TREMFYA open payments reported associated product |
CMS Open Payments — General Payments 292917 supporting records · 40097 recipient NPIs · example record 1174257364 |
Tremfya · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 2529 | 515 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 2063 | 249 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 1014 | 127 |
| Tizanidine Hcl | Tizanidine Hcl | 952 | 186 |
| Gabapentin | Gabapentin | 894 | 150 |
| Tramadol Hcl | Tramadol Hcl | 718 | 129 |
| Prednisone | Prednisone | 642 | 123 |
| Leflunomide | Leflunomide | 634 | 137 |
| Alprazolam | Alprazolam | 509 | 72 |
| Methotrexate | Methotrexate Sodium | 497 | 98 |
| Clonazepam | Clonazepam | 482 | 72 |
| Meloxicam | Meloxicam | 460 | 106 |
| Zolpidem Tartrate | Zolpidem Tartrate | 456 | 74 |
| Duloxetine Hcl | Duloxetine Hcl | 441 | 93 |
| Diclofenac Sodium | Diclofenac Sodium | 383 | 97 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 381 | 90 |
| Quetiapine Fumarate | Quetiapine Fumarate | 347 | 65 |
| Oxycodone Hcl | Oxycodone Hcl | 341 | 39 |
| Levothyroxine Sodium | Levothyroxine Sodium | 339 | 69 |
| Pregabalin | Pregabalin | 282 | 54 |
| Allopurinol | Allopurinol | 252 | 62 |
| Trazodone Hcl | Trazodone Hcl | 248 | 55 |
| Methocarbamol | Methocarbamol | 236 | 65 |
| Methylprednisolone | Methylprednisolone | 231 | 120 |
| Celecoxib | Celecoxib | 213 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 209 | 53 |
| Atorvastatin Calcium | Atorvastatin Calcium | 185 | 39 |
| Rinvoq | Upadacitinib | 168 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 142 | 32 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 140 | 15 |
| Omeprazole | Omeprazole | 131 | 24 |
| Ondansetron Odt | Ondansetron | 131 | 39 |
| Pilocarpine Hcl | Pilocarpine Hcl | 129 | 43 |
| Temazepam | Temazepam | 129 | 24 |
| Methylphenidate Hcl | Methylphenidate Hcl | 125 | 18 |
| Lorazepam | Lorazepam | 124 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 123 | 22 |
| Propranolol Hcl | Propranolol Hcl | 115 | 23 |
| Cevimeline Hcl | Cevimeline Hcl | 112 | 25 |
| Promethazine Hcl | Promethazine Hcl | 109 | 31 |
| Clobetasol Propionate | Clobetasol Propionate | 104 | 42 |
| Risedronate Sodium | Risedronate Sodium | 98 | 33 |
| Diazepam | Diazepam | 94 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 93 | 23 |
| Sertraline Hcl | Sertraline Hcl | 90 | 19 |
| Sumatriptan Succinate | Sumatriptan Succinate | 88 | 21 |
| Losartan Potassium | Losartan Potassium | 84 | 20 |
| Ibandronate Sodium | Ibandronate Sodium | 80 | 28 |
| Valacyclovir | Valacyclovir Hcl | 80 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 79 | 15 |
| Furosemide | Furosemide | 77 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 77 | 27 |
| Potassium Chloride | Potassium Chloride | 77 | 18 |
| Ibuprofen | Ibuprofen | 75 | 18 |
| Montelukast Sodium | Montelukast Sodium | 75 | 17 |
| Enbrel Sureclick | Etanercept | 72 | suppressed |
| Carisoprodol | Carisoprodol | 70 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 70 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 70 | 12 |
| Fluconazole | Fluconazole | 69 | 32 |
| Baclofen | Baclofen | 68 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 66 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 64 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 63 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 63 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 63 | suppressed |
| Naproxen | Naproxen | 63 | 13 |
| Modafinil | Modafinil | 62 | 19 |
| Amlodipine Besylate | Amlodipine Besylate | 61 | 14 |
| Lidocaine | Lidocaine | 60 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 60 | 31 |
| Prolia | Denosumab | 59 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 58 | 18 |
| Bupropion Xl | Bupropion Hcl | 58 | 13 |
| Famotidine | Famotidine | 58 | 17 |
| Xeljanz Xr | Tofacitinib Citrate | 58 | 11 |
| Minocycline Hcl | Minocycline Hcl | 55 | 13 |
| Estradiol | Estradiol | 54 | 12 |
| Topiramate | Topiramate | 54 | 14 |
| Alendronate Sodium | Alendronate Sodium | 51 | 14 |
| Sulfasalazine | Sulfasalazine | 51 | suppressed |
| Colchicine | Colchicine | 50 | 17 |
| Humira(Cf) Pen | Adalimumab | 50 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 50 | 14 |
| Cimzia (2 Pack) | Certolizumab Pegol | 49 | suppressed |
| Mirtazapine | Mirtazapine | 46 | suppressed |
| Folic Acid | Folic Acid | 45 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 13 |
| Enbrel | Etanercept | 44 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 44 | 14 |
| Orencia Clickject | Abatacept | 44 | suppressed |
| Eszopiclone | Eszopiclone | 43 | suppressed |
| Atenolol | Atenolol | 42 | suppressed |
| Lisinopril | Lisinopril | 42 | 13 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 41 | suppressed |
| Benlysta | Belimumab | 40 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 39 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 38 | suppressed |
| Nystatin | Nystatin | 38 | 22 |
| Meclizine Hcl | Meclizine Hcl | 37 | suppressed |
| Azathioprine | Azathioprine | 34 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | suppressed |
| Methylprednisolone Sodium Succ | Methylprednisolone Sod Succ | 34 | suppressed |
| Linzess | Linaclotide | 32 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 32 | suppressed |
| Methotrexate Sodium | Methotrexate Sodium/Pf | 32 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 32 | suppressed |
| Acyclovir | Acyclovir | 31 | suppressed |
| Armodafinil | Armodafinil | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | suppressed |
| Sulfasalazine Dr | Sulfasalazine | 30 | suppressed |
| Xtampza Er | Oxycodone Myristate | 29 | suppressed |
| Famciclovir | Famciclovir | 28 | suppressed |
| Pentoxifylline | Pentoxifylline | 28 | suppressed |
| Metformin Hcl | Metformin Hcl | 27 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 27 | 14 |
| Otezla | Apremilast | 27 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 26 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 26 | suppressed |
| Nabumetone | Nabumetone | 26 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 26 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 24 | suppressed |
| Actemra | Tocilizumab | 23 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 18 |
| Enbrel Mini | Etanercept | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Humira Pen | Adalimumab | 21 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 21 | 13 |
| Rizatriptan | Rizatriptan Benzoate | 21 | suppressed |
| Clotrimazole | Clotrimazole | 20 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Pentazocine-Naloxone Hcl | Pentazocine Hcl/Naloxone Hcl | 20 | suppressed |
| Plaquenil | Hydroxychloroquine Sulfate | 20 | suppressed |
| Savella | Milnacipran Hcl | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Methadone Hcl | Methadone Hcl | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 18 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Tremfya | Guselkumab | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Carvedilol | Carvedilol | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Febuxostat | Febuxostat | 15 | suppressed |
| Hydrocortisone Butyrate | Hydrocortisone Butyrate | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 14 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 14 | 14 |
| Orencia | Abatacept/Maltose | 14 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 13 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Misoprostol | Misoprostol | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Simvastatin | Simvastatin | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Butalbital-Acetaminophen | Butalbital/Acetaminophen | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 12 | suppressed |
| Humira | Adalimumab | 12 | suppressed |
| Nexium | Esomeprazole Magnesium | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Restasis Multidose | Cyclosporine | 12 | suppressed |
| Saphnelo | Anifrolumab-Fnia | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Eliquis | Apixaban | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $222,385.59 · 212 records | ABBVIE INC. | ACTHAR, BENLYSTA, Bimzelx, COSENTYX, CUTAQUIG, ENBREL, EVENITY, HADLIMA, Hizentra, KEVZARA, KRYSTEXXA, LUPKYNIS, NEXPLANON, NURTEC ODT, OCTAGAM IMMUNE GLOBULIN (HUMAN), OFEV, ORENCIA, OTEZLA, PANZYGA, PROLIA, QULIPTA, RELISTOR, RINVOQ, SAPHNELO, SKYRIZI, SOVUNA, Sunosi, TALTZ, TAVNEOS, TONMYA, TREMFYA, UBRELVY, UPLIZNA, VELSIPITY, VRAYLAR, XELJANZ, ZAVZPRET, ZEPBOUND, ZTLido | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Benlysta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error